Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Mesoblast LimitedNASDAQ: MESO

Investing Cash Flow · Q4 FY2026 · quarter ended Jun 2026

Investing cash flow declines year over year

Q4 FY2026 investing cash flow of $64K (cash outflow) fell 85.5% year over year, ahead of the -952.5% change in trailing-twelve-month investing cash flow. Sequentially, it fell 81.8% from the prior quarter. Over 3 fiscal years it compounded at +74.1% a year.

Context

  • Investing cash flow amounted to 0.8% of revenue in FY2026, up 0.1 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -85.5% holds above the trailing-twelve-month pace of -952.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$64K-81.8% QoQ
Last fiscal yearJun 2026
-$1.02M-952.5% YoY
LTMJun 2026
-$1.02M-952.5% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-85.5%——
1 year-952.5%——
3-year CAGR+74.1%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2026
(1.02M) USD
Year-over-year change
-952.5%

Investing Cash Flow vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 investing cash flow of $1.02M is the 5th largest of the 6 companies compared; the peer median is $0.
  • Its year-over-year change of -952.5% is the lowest of 6, against a peer median of +145.0%.
  • Investing cash flow amounts to 0.9% of revenue for MESO, versus a peer median of 68.2%.
MESO Competitors Peer median
Investing Cash Flow for MESO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$226.82M +1455.9%—16.7%
FATEFate Therapeutics, Inc.LTM Mar 2026$92.08M +145.0%-12.6%1457.9%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$81.05M -2.1%——
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$17.69M +4719.1%-33.7%119.7%
MESOMesoblast LimitedLTM Jun 2026$1.02M -952.5%+74.1%0.9%
CELUCelularity Inc.LTM Dec 2025$0 -100.0%—0.0%
Peer median (excluding MESO) $0+145.0%-23.2%68.2%

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income(91.35M)(81.89M)(87.96M)(102.14M)0
Depreciation & Amortization4.38M4.11M4.67M6.4M0
Deferred Income Tax(235K)(212K)(191K)330K0
Stock-Based Compensation5.54M3.66M5.87M22.09M0
Change in Working Capital4.87M(2.47M)(2.63M)(3.04M)0
Accounts Receivables140K(118K)(15.47M)6.29M0
Inventory000826K0
Accounts Payables00000
Other Working Capital4.73M(2.35M)12.84M(10.16M)0
Other Non-Cash Items11.02M13.54M31.78M26.41M(43.83M)
Operating Cash Flow(65.78M)(63.27M)(48.46M)(49.95M)(43.83M)
Capital Expenditures(232K)(314K)(331K)(730K)(898K)
Acquisitions (Net)00000
Purchases of Investments0000(125K)
Sales of Investments0120K234K241K0
Other Investing Activities(75K)120K(60K)559K(65K)
Investing Cash Flow(232K)(194K)(97K)120K(1.02M)
Debt Repayment(6.33M)(2.66M)(13.52M)(9.77M)(5.94M)
Common Stock Issued209K88.64M65.41M161.21M14.24M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.75M)(11.48M)(11.63M)(4.1M)(23.64M)
Financing Cash Flow(9.87M)74.5M40.25M147.34M(15.33M)
Effect of Forex Changes(550K)(168K)(55K)1.09M1.55M
Net Change in Cash(76.43M)10.87M(8.36M)98.59M(58.64M)
Free Cash Flow(66.01M)(63.58M)(48.79M)(50.68M)(44.73M)

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.